Nur für die Forschung bestimmt

Deferoxamine mesylate Ferroptosis Inhibitor

Name: Deferoxamine mesylate
Brand: Selleck Chemicals
SKU: S5742
Rating: 5 (117 reviews)

Kat.-Nr.: S5742

Deferoxamine mesylate ist das Mesylatsalz von Deferoxamine, das Eisenkomplexe bildet und als Chelatbildner verwendet wird. Deferoxamine ist ein Ferroptosis-Inhibitor, der die HIF-1α-Expression stabilisiert und die HIF-1α-Transaktivität in hypoxischen und hyperglykämischen Zuständen in vitro verbessert. Deferoxamine reduziert die Beta-Amyloid (Aβ)-Ablagerung und induziert Autophagy.Bitte bereiten Sie keine Stammlösungen mit normaler Kochsalzlösung oder PBS zu, da es zu Ausfällungen kommen kann.

Deferoxamine mesylate Ferroptosis Inhibitor Chemical Structure

Chemische Struktur

Molekulargewicht: 656.79

Springen zu

Qualitätskontrolle (Quality Control)

Charge: Reinheit: 99.74%

99.74

Produkte, die oft zusammen verwendet werden mit Deferoxamine mesylate

Z-VAD-FMK

It can reverse the cell proliferative activity of granulosa cells in EMFF but not Z-VAD-FMK.

Ferrostatin-1 (Fer-1)

It and Ferrostatin-1 can reverse the cell proliferative activity of granulosa cells in EMFF.

SRS11-92

It can reverse the cell proliferative activity of granulosa cells in EMFF but not Necrostatin-1.

Verwandte Targets	CXCR Autophagy Nrf2 Mitophagy LRRK2 ULK FKBP Heme Oxygenase cGAS LC3
Andere Ferroptosis Inhibitors	Liproxstatin-1 RSL3 Erastin Imidazole Ketone Erastin (IKE) FIN56 UAMC-3203 iFSP1 N6F11 SRS16-86 icFSP1

Zellkultur, Behandlung & Arbeitskonzentration
(Cell Culture, Treatment & Working Concentration)

Zelllinien	Assay-Typ	Konzentration	Inkubationszeit	Aktivitätsbeschreibung	PMID
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM.	17602603
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM.	19601577
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM.	19216562
A549	Antiproliferative assay		72 hrs	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM.	22861499
SK-N-MC	Antiproliferative assay		96 hrs	Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM.	17064069
MDCK	Toxicity assay			Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM.	20041672
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM.	20303768
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
DMS53	Antiproliferative assay		72 hrs	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
SK-MN-C	Antiproliferative assay			Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM.	18159922
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM.	22858101
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM.	17963372
SK-N-MC	Toxicity assay			Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM.	20041672
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM.	28841514
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	21055950
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	22172311
U2OS	Function assay		30 mins	Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM.	22172704
HL60	Cytotoxicity assay			Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM.	23266185
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM.	23312948
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM.	19601577
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM.	21846118
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM.	23276209
K562	Cytotoxicity assay			Cytotoxicity against human K562 cells, GI50 = 33.1 μM.	23266185
HT29	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM.	18345610
HT-29	Cell cycle assay	10 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs	20353152
HT-29	Cell cycle assay	5 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs	20353152
HCT116	Function assay		24 hrs	Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3	24900837
HeLa	Bacteriostatic assay	>100 uM	1 hr	Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy	25027937
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay	28285915
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Klicken Sie hier, um weitere experimentelle Zellliniendaten anzuzeigen

Chemische Informationen, Lagerung & Stabilität (Chemical Information, Storage & Stability)

Molekulargewicht	656.79	Formel	C₂₆H₅₂N₆O₁₁S	Lagerung (Ab Erhaltdatum)	3 years -20°C powder
CAS-Nr.	138-14-7	--		Lagerung von Stammlösungen	1 Jahr-80°Cin Lösungsmittel 1 Monat-20°Cin Lösungsmittel

Löslichkeit (Solubility)

In vitro
Charge:

DMSO : 100 mg/mL (152.25 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

DMSO : 100 mg/mL (152.25 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

DMSO : 100 mg/mL (152.25 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

DMSO : 100 mg/mL (152.25 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Water : 100 mg/mL

DMSO : 50 mg/mL (76.12 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Ethanol : Insoluble

Molaritätsrechner

Masse	Konzentration	Volumen	Molekulargewicht
=	×	×

Verdünnungsrechner Molekulargewicht-Rechner

In vivo Charge:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Von Selleck-Laboren validiert. Sollten Sie Anpassungen an dieser Formulierung benötigen, wenden Sie sich für kundenspezifische Tests an unser Vertriebsteam.	5.000mg/ml (7.61mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In-vivo-Formulierungsrechner (Klare Lösung)

Schritt 1: Geben Sie unten die Informationen ein (Empfohlen: Ein zusätzliches Tier einplanen, um Verluste während des Experiments auszugleichen)

Dosierung: mg/kg Durchschnittliches Gewicht der Tiere: g Dosierungsvolumen pro Tier:μL Anzahl der Tiere:

Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, nicht die Formulierung. Bitte kontaktieren Sie uns zuerst, wenn im Abschnitt Löslichkeit keine In-vivo-Formulierung angegeben ist.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berechnungsergebnisse:

Arbeitskonzentration: mg/ml;

Methode zur Herstellung der DMSO-Stammflüssigkeit: mg Wirkstoff voraufgelöst in μL DMSO ( Konzentration der Stammflüssigkeit mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der jeweiligen Wirkstoffcharge überschreitet. )

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammflüssigkeit, fügen Sie als Nächstes hinzuμL PEG300, mischen und aufklären, fügen Sie als Nächstes hinzuμL Tween 80, mischen und aufklären, fügen Sie als Nächstes hinzu μL ddH₂O, mischen und aufklären.

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammflüssigkeit, fügen Sie als Nächstes hinzu μL Maisöl, mischen und aufklären.

Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, die Lösungsmittel in der richtigen Reihenfolge hinzuzufügen. Sie müssen sicherstellen, dass die im vorherigen Schritt erhaltene Lösung klar ist, bevor Sie das nächste Lösungsmittel hinzufügen. Physikalische Methoden wie Vortexen, Ultraschall oder ein warmes Wasserbad können zur Unterstützung des Lösungsvorgangs verwendet werden.

Wirkungsmechanismus (Mechanism of Action)

Targets/IC₅₀/Ki	HIF-1α Beta Amyloid Ferroptosis
In vitro	Deferoxamine mesylate, the iron chelator and ferroptosis inhibitor, rescues neutrophil death induced by systemic lupus erythematosus (SLE) serum, suggesting that ferroptosis may be the main form of neutrophil death in SLE.
In vivo	Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468) is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent.
Referenzen	[1] https://pubmed.ncbi.nlm.nih.gov/26082716/ [2] https://pubmed.ncbi.nlm.nih.gov/30539824/ [3] https://pubmed.ncbi.nlm.nih.gov/34385713/ [4] https://pubmed.ncbi.nlm.nih.gov/2538902/

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Deferoxamine mesylate Ferroptosis Inhibitor

Molekulargewicht: 656.79

Qualitätskontrolle (Quality Control)

Produkte, die oft zusammen verwendet werden mit Deferoxamine mesylate

Zellkultur, Behandlung & Arbeitskonzentration (Cell Culture, Treatment & Working Concentration)

Chemische Informationen, Lagerung & Stabilität (Chemical Information, Storage & Stability)

Löslichkeit (Solubility)

Molaritätsrechner

In-vivo-Formulierungsrechner (Klare Lösung)

Wirkungsmechanismus (Mechanism of Action)

Zellkultur, Behandlung & Arbeitskonzentration
(Cell Culture, Treatment & Working Concentration)